MM-310
- Generic Name
- MM-310
A Study Evaluating MM-310 in Patients With Solid Tumors
Phase 1
- Conditions
- Solid TumorsOvarian CancerTriple Negative Breast CancerSoft Tissue SarcomaUrothelial CarcinomaGastric CarcinomaSquamous Cell Carcinoma of the Head and NeckEndometrial CarcinomaPancreatic Ductal AdenocarcinomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT03076372
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸University California San Francisco, San Francisco, California, United States
🇺🇸Honor Health, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath